ERBB2 and endometrial cancer: Combination therapy with HER2-directed monoclonal antibodies and standard platinum and taxane-based chemotherapy has significantly improved treatment outcomes in advanced and recurrent HER2 amplified CNH endometrial cancer (Fader, 2020).